Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 5, 2014, Pages 617-624

  Idilman, Ilkay S ^a   Keskin, Onur ^b   Elhan, Atilla Halil ^b   Idilman, Ramazan ^b   Karcaaltincaba, Musturay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Department of Gastroenterology ^*  (Turkey)

Author keywords

Follow up; Hepatic steatosis; MRI; Nonalcoholic fatty liver disease; PDFF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; PROTON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FAT CONTENT; FATTY LIVER; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMAGE PROCESSING; INSULIN RESISTANCE; LIMIT OF QUANTITATION; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBESITY; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; SEQUENTIAL PROTON DENSITY FAT FRACTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TIME;

ADIPOSITY; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTONS; TIME FACTORS;

EID: 84898945178     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.894118     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31
2. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-58. (Pubitemid 40037633
3. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease andnonalcoholicsteatohepatitis:selectedpracticalissuesintheir evaluation and management. Hepatology 2009;49:306-17
4. Bravo A, Sheth S, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500. (Pubitemid 32164902
5. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-906. (Pubitemid 40824701
6. Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV. Accuracy of liver fat quantification at MR imaging: Comparison of out-of-phase gradient echo and fat-saturated fast spin-echo techniques-initial experience. Radiology 2005;237:507-11. (Pubitemid 41507887
7. Pilleul F, Chave G, Dumortier J, Scoazec JY, Valette PJ. Fatty infiltration of the liver: Detection and grading using dual T1 gradient echo sequences on clinical MR system. Gastroenterol Clin Biol 2005;29:1143-7. (Pubitemid 43046359
8. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189-94. (Pubitemid 14043406
9. Glover GH. Multipoint Dixon technique for water and fat proton and susceptibility imaging. J Magn Reson Imaging 1991;5:521-30
10. Bley TA, Wieben O, François CJ, Brittain JH, Reeder SB. Fat and water magnetic resonance imaging. J Magn Reson Imaging 2010;31:4-18
11. Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am 2010;18:337-57
12. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011;34:729-49
13. Reeder SB, Robson PM, Yu H, Schimakawa A, Hines CD, McKenzie CA, et al. Quantification of hepatic steatosis with MRI: The effects of accurate fat spectral modeling. J Magn Reson Imaging 2009;29:1332-9
14. Yokoo T, Bydder M, Hamilton G, Middelton MS, Gamst AC, Wolfson T, et al. Nonalcoholic fatty liver disease: Diagnostic fat-grading accuracy of low-flip-Angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009;251:67-76
15. Kim H, Taksali SE, Dufour S, Befroy D, Goodman TR, Petersen KF, et al. Comparative MR study of hepatic fat quantification using single voxel proton spectroscopy, two point Dixon and three-point IDEAL. Magn Reson Med 2008;59:521-7. (Pubitemid 351348223
16. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22-9
17. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013;267:422-31
18. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767-75
19. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, et al. Longitudinal comparison between MRI, MRS and histology-Determined steatosis in NAFLD patients at two-Time points in a randomized trial. Hepatology 2013;58:1930-40
20. World Health Organization. Report of a WHO consultation: Definition of metabolic syndrome in definition, diagnosis and classification of diabetes mellitus. Geneva: World Health organization, Department of Noncommunicable Disease Surveillance; 1999
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19. (Pubitemid 15018832
22. Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284
23. Yu H, McKenzie CA, Shimakawa A, Vu AT, Brau AC, Beattu BJ, et al. Multiecho reconstruction for simultaneous water-fat decomposition and T2. estimation. J Magn Reson Imaging 2007;26:1153-61. (Pubitemid 47548182
24. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27: 103-7. (Pubitemid 27357062
25. Kukkonen K, Rauramaa R, Siitonen O, Hänninen O. Physical training of obese middle-Aged persons. Ann Clin Res 1982;34:80-5. (Pubitemid 12016888
26. Bydder M, Shiehmorteza M, Yokoo T, Sugay S, Middleton MS, Girard O, et al. Assessment of liver fat quantification in the presence of iron. Magn Reson Imaging 2010;28:767-76
27. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995;5:281-5
28. Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, et al. Chronic hepatitis: In vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001;221:740-6. (Pubitemid 33101766
29. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-Alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17. (Pubitemid 37221684
30. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with non-Alcoholic steatohepatitis. N Engl J Med 2006;355:2297-307. (Pubitemid 44837778
31. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44. (Pubitemid 38387180
32. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: Insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-8. (Pubitemid 351861962
33. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008;48:119-28. (Pubitemid 351975537
34. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9
35. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8. (Pubitemid 40038911
36. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-Alcoholic fatty liver. J Hepatol 2013;59:550-6